First Health Canada Approved Medical Cannabis Clinical Trial Starts Patient Recruitment

Landmark trial will be first to study safety and efficacy of a series of cannabinoid profiles

SASKATOON, June 23, 2015 /CNW/ - Prairie Plant Systems and CanniMed, Canada's most well-established and reliable producer of medical cannabis, along with researchers at McGill University Health Centre and Dalhousie Universities, officially start patient engagement today on the CAPRI Trial (Cannabinoid Profile Investigation of Vaporized Cannabis in Patients with Osteoarthritis of the Knee), a randomized, double blind, placebo controlled, proof-of-concept, crossover clinical trial of single dose vaporized cannabis in adults with painful osteoarthritis of the knee.

Not only was this clinical trial the first to be registered with Health Canada after the transition to the new Marihuana for Medical Purposes Regulations (MMPR), CAPRI will seek to understand the analgesic dose-response of several varieties of medical cannabis, consisting of varying concentrations of the two most common active ingredients: delta-9-tetrahydrocannabinol...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.


URL: 
http://www.newswire.ca/en/story/1560587/first-health-canada-approved-medical-cannabis-clinical-trial-starts-patient-recruitment